1. Home
  2. HLP vs CALC Comparison

HLP vs CALC Comparison

Compare HLP & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hongli Group Inc.

HLP

Hongli Group Inc.

HOLD

Current Price

$0.99

Market Cap

76.4M

Sector

Industrials

ML Signal

HOLD

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

N/A

Current Price

$0.80

Market Cap

88.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HLP
CALC
Founded
2021
2011
Country
China
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
76.4M
88.3M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
HLP
CALC
Price
$0.99
$0.80
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
80.4K
479.8K
Earning Date
09-30-2025
03-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$51.63
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.61
$0.46
52 Week High
$1.72
$7.20

Technical Indicators

Market Signals
Indicator
HLP
CALC
Relative Strength Index (RSI) 46.39 36.73
Support Level $0.64 $0.49
Resistance Level $1.10 $0.79
Average True Range (ATR) 0.07 0.09
MACD -0.01 0.13
Stochastic Oscillator 22.75 64.54

Price Performance

Historical Comparison
HLP
CALC

About HLP Hongli Group Inc.

Hongli Group Inc is a cold roll-formed steel profile manufacturer in China. It customizes and manufactures cold roll-formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture, and transportation. Geographically, the company generates the majority of its revenue from the PRC.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

Share on Social Networks: